229 related articles for article (PubMed ID: 25574958)
1. Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approach.
Lamorde M; Schapiro JM; Burger D; Back DJ
AIDS; 2014 Nov; 28(17):2551-63. PubMed ID: 25574958
[TBL] [Abstract][Full Text] [Related]
2. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK;
N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366
[TBL] [Abstract][Full Text] [Related]
3. Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy.
Goodman DD; Zhou Y; Margot NA; McColl DJ; Zhong L; Borroto-Esoda K; Miller MD; Svarovskaia ES
AIDS; 2011 Jan; 25(3):325-33. PubMed ID: 21157296
[TBL] [Abstract][Full Text] [Related]
4. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
Marcelin AG; Charpentier C; Wirden M; Landman R; Valantin MA; Simon A; Katlama C; Yeni P; Descamps D; Aubron-Olivier C; Calvez V
J Antimicrob Chemother; 2012 Jun; 67(6):1475-8. PubMed ID: 22371439
[TBL] [Abstract][Full Text] [Related]
5. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS;
J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763
[TBL] [Abstract][Full Text] [Related]
6. Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
Di Biagio A; Prinapori R; Giannarelli D; Maggiolo F; Di Giambenedetto S; Borghi V; Penco G; Cicconi P; Francisci D; Sterrantino G; Zoncada A; Monno L; Capetti A; Giacometti A;
J Antimicrob Chemother; 2013 Jan; 68(1):200-5. PubMed ID: 22915463
[TBL] [Abstract][Full Text] [Related]
7. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
8. Viro-immunological response and emergence of resistance in HIV-infected women receiving combination antiretroviral regimens for the prevention of mother-to-child transmission in Malawi.
Palombi L; Galluzzo CM; Pirillo MF; Liotta G; Andreotti M; Jere H; Sagno JB; Luhanga R; Mancinelli S; Ceffa S; Amici R; Marazzi MC; Vella S; Giuliano M
J Antimicrob Chemother; 2014 Mar; 69(3):749-52. PubMed ID: 24135952
[TBL] [Abstract][Full Text] [Related]
9. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H
Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
Sánchez-de la Rosa R; Herrera L; Moreno S
Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
[TBL] [Abstract][Full Text] [Related]
11. Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz.
Cooper V; Moyle GJ; Fisher M; Reilly G; Ewan J; Liu HC; Horne R;
AIDS Care; 2011 Jun; 23(6):705-13. PubMed ID: 21476152
[TBL] [Abstract][Full Text] [Related]
12. Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine.
Havlir DV; Koelsch KK; Strain MC; Margot N; Lu B; Ignacio CC; Miller MD; Wong JK;
J Infect Dis; 2005 Apr; 191(7):1164-8. PubMed ID: 15747253
[TBL] [Abstract][Full Text] [Related]
13. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.
Shafer RW; Smeaton LM; Robbins GK; De Gruttola V; Snyder SW; D'Aquila RT; Johnson VA; Morse GD; Nokta MA; Martinez AI; Gripshover BM; Kaul P; Haubrich R; Swingle M; McCarty SD; Vella S; Hirsch MS; Merigan TC;
N Engl J Med; 2003 Dec; 349(24):2304-15. PubMed ID: 14668456
[TBL] [Abstract][Full Text] [Related]
14. Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months.
Boothby M; McGee KC; Tomlinson JW; Gathercole LL; McTernan PG; Shojaee-Moradie F; Umpleby AM; Nightingale P; Shahmanesh M
Antivir Ther; 2009; 14(8):1089-100. PubMed ID: 20032539
[TBL] [Abstract][Full Text] [Related]
15. Resistance to antiretrovirals in HIV-infected pregnant women.
Weinberg A; Forster-Harwood J; McFarland EJ; Pappas J; Davies JK; Kinzie K; Barr EA; Paul SM; Salbenblatt CR; Soda E; Vazquez A; Levin MJ
J Clin Virol; 2009 May; 45(1):39-42. PubMed ID: 19329355
[TBL] [Abstract][Full Text] [Related]
16. [Budget impact of a set-dose combination of efavirenz-emtricitabine-tenofovir in the treatment of patients infected with HIV-1].
Oyagüez I; Casado MA; Cotarelo M; Ramírez-Arellano A; Mallolas J
Farm Hosp; 2009; 33(5):247-56. PubMed ID: 19775575
[TBL] [Abstract][Full Text] [Related]
17. Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi.
Palombi L; Pirillo MF; Marchei E; Jere H; Sagno JB; Luhanga R; Floridia M; Andreotti M; Galluzzo CM; Pichini S; Mwenda R; Mancinelli S; Marazzi MC; Vella S; Liotta G; Giuliano M
J Antimicrob Chemother; 2016 Apr; 71(4):1027-30. PubMed ID: 26679247
[TBL] [Abstract][Full Text] [Related]
18. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
Gulick RM; Lalama CM; Ribaudo HJ; Shikuma CM; Schackman BR; Schouten J; Squires KE; Koletar SL; Pilcher CD; Reichman RC; Klingman KL; Kuritzkes DR
AIDS; 2007 Apr; 21(7):813-23. PubMed ID: 17415036
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
Brogan AJ; Talbird SE; Cohen C
Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
Vourvahis M; Davis J; Langdon G; Layton G; Fang J; Choo HW; Hansson AG; Tawadrous M
Antivir Ther; 2013; 18(6):745-54. PubMed ID: 23558061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
